Chenggong Li

Statistics

Publications

Citations

846

H-Index

Active since

2017

Affiliations

Huazhong University of Science and Technology(Current)

Hubei Cancer Hospital

Union Hospital

Wuhan Union Hospital

Chenggong Li is an author at Huazhong University of Science and Technology specializing in cancer immunotherapy, medicine, and chimeric antigen receptor t-cell therapy.

Publications per year

2017–2025

Publications

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma

Heng Mei, Chenggong Li, Huiwen Jiang et al. · Journal of Hematology & Oncology · 2021 · 225 citations · Full text

Medicine, Immunology, Oncology +16

Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trial

Huiwen Jiang, Chenggong Li, Ping Yin et al. · American Journal of Hematology · 2019 · 137 citations · Full text

Medicine, Hematology, Oncology +17

A miR-20a/MAPK1/c-Myc regulatory feedback loop regulates breast carcinogenesis and chemoresistance

Wengong Si, Jiaying Shen, Chengyong Du et al. · Cell Death and Differentiation · 2017 · 93 citations · Full text

Medicine, Cancer Biology, Oncology +17

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Chenggong Li, Heng Mei, Yu Hu et al. · Blood · 2019 · 83 citations

Medicine, Hematology, Oncology +16

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

Yinqiang Zhang, Chenggong Li, Mengyi Du et al. · Blood Cancer Journal · 2023 · 78 citations · Full text

Medicine, Hematology, Oncology +16

1–5 of 14